HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,621-7,632 of 27,277
Drug study icon
CompletedNCT02431702

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Official study title

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–35
Countries
United States, Brazil, Mexico
Sponsor
Janssen Scientific Affairs, LLC
Drug study icon
CompletedNCT00210717

Paliperidone or long-acting risperidone injections for schizophrenia over one year

About this title

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Read the official source — NCT00210717
Official study title

A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00645372

Ziprasidone or risperidone for schizophrenia in China

About this title

A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

Read the official source — NCT00645372
What is this study about?

Researchers compared Ziprasidone and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
CompletedNCT03321526

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in adults with Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

What is this study about?

This study evaluated the safety and effectiveness of JNJ-42847922 for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Phoenix
DepressionMedication studyAges 18–70
Countries
United States
Sponsor
Janssen Research & Development, LLC
Drug study icon
CompletedNCT01654601

A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg

Official study title

Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

This study has finished and is no longer accepting participants.

Multiple locations, including Choongju
SchizophreniaMedication studyAges 20–60
Countries
South Korea
Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Other study type icon
CompletedNCT00392743

Comparing two brain scans in people with schizophrenia

About this title

A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients

Read the official source — NCT00392743
Official study title

An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders

This study has finished and is no longer accepting participants.

Multiple locations, including Barcelona
SchizophreniaObservational studyAges 18+
Countries
Spain
Sponsor
GlaxoSmithKline
Drug study icon
WithdrawnNCT02418702

A Study to Decrease Suicidal Thinking Using Ketamine

Official study title

A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine

This study was withdrawn before enrollment.

In San Diego
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
United States Naval Medical Center, San Diego
Other study type icon
CompletedNCT04463108

A Study to Describe Routine Treatment Pathways in people with Major Depression and Active Suicide prevention With Intent in Italy

Official study title

A Description of Routine Treatment Pathways in a Cohort of Patients With Major Depression and "Active Suicidal Ideation With Intent" in Italy: the Arianna Observational Study.

This study has finished and is no longer accepting participants.

Multiple locations, including Brescia
Depression, SuicidalityObservational studyAges 18–74
Countries
Italy
Sponsor
Janssen-Cilag S.p.A.
Drug study icon
CompletedNCT00518232

Switching children with ADHD to extended-release methylphenidate

About this title

A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder

Read the official source — NCT00518232
Official study title

The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDMedication studyAges 6–19
Countries
Sponsor
Johnson & Johnson Taiwan Ltd
Drug study icon
CompletedNCT03751488

Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Official study title

A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Luye Pharma Group Ltd.
Drug study icon
CompletedNCT00212797

Two doses of Org 34517 compared with placebo for psychotic depression

About this title

A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)

Read the official source — NCT00212797
What is this study about?

This study evaluated the safety and effectiveness of Org 34517 for people with depression.

This study has finished and is no longer accepting participants.

Location not clearly listed
Depression, SchizophreniaMedication studyAges 18–70
Countries
Sponsor
Merck Sharp & Dohme LLC

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.